Press Releases

Showing 211-245 of 252


2011

May

May 10

Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study

May 6

Abbott Receives FDA Approval to Expand Use of the RX ACCULINK® Carotid Stent System to Patients at Standard Surgical Risk

May 3

Abbott to Present at Bank of America Merrill Lynch 2011 Health Care Conference
 

April

April 29

Abbott Highlights Top-Tier Financial Performance, Strong Growth in Emerging Markets at Annual Meeting

April 29

Abbott Receives U.S. FDA Approval for AndroGel® 1.62% to Treat Men with Low Testosterone

April 20

Abbott Reports 17.4 Percent Sales Growth and 12.3 Percent Ongoing Earnings-Per-Share Growth in First Quarter

April 19

Abbott Chairman and CEO Miles D. White Elected to the American Academy of Arts & Sciences

April 15

New Fully Automated Vitamin D Assay Submitted for FDA Clearance

April 12

Abbott Recognized As Company of the Year for Global Halal Initiatives

April 4

Data from Landmark Clinical Trial of Abbott's MitraClip® System Demonstrate Durable Clinical Benefits for Patients with Mitral Regurgitation Two Years After Treatment

April 4

Abbott's ABSORB Bioresorbable Vascular Scaffold Demonstrates Positive One-Year Safety and Efficacy Results

April 4

Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C

April 3

Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®
 

March

March 31

Abbott Hosts Conference Call for First-Quarter Earnings

March 31

Abbott Introduces Hepatitis B Sequencing Test in Europe

March 30

Abbott Announces Launch of Catheter-Based MitraClip® System in Australia for Mitral Regurgitation, the Most Common Heart Valve Condition

March 28

Abbott to Present Data on Novel Vascular Technologies and XIENCE V® at ACC 2011

March 28

Abbott Introduces Micro-Implantation Cataract Suite

March 24

Abbott Recognizes Winners of Supplier Excellence Award

March 21

Abbott's New HIV-1 Qualitative Assay Improves Testing Access in Remote Areas for Children and Adults

March 14

Abbott Supports Relief Efforts in Japan

March 4

Positive Results from Phase 2 Study of Atrasentan for Treatment of Diabetic Kidney Disease Published in the Journal of the American Society of Nephrology

March 1

Abbott to Present at Barclays Capital 2011 Global Healthcare Conference
 

February

February 22

Abbott to Present at Cowen and Company 31st Annual Health Care Conference

February 22

Abbott Launches a CE Marked KIF6 Test in Europe

February 18

Abbott Announces Increase in Quarterly Dividend

February 15

Abbott to Present at RBC Capital Markets' Healthcare Conference

February 7

Abbott Introduces Biothreat Assay for PLEX-ID™ System

February 7

Abbott’s Ibis Technology Identified Fatal Disease Organism in Afghanistan
 

January

January 31

Abbott's TREK® Coronary Balloon System Now Available in the United States and Japan

January 26

Abbott Reports Double-Digit Sales and Ongoing Earnings Growth in Fourth Quarter; Issues Ongoing Earnings Outlook for 2011

January 26

FDA Advisory Committee Votes Favorably on Expanding the Indication for Abbott's Carotid Stent System to Include Patients at Standard Surgical Risk

January 25

New Abbott Vitamin D Test Available for Use in the European Union

January 10

Abbott Receives CE Mark Approval for World's First  Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease

January 7

Partners In Health, Abbott and the Abbott Fund Unite to Combat Severe Childhood Malnutrition in Haiti